BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

428 related articles for article (PubMed ID: 37822927)

  • 41. Characterization of a cuproptosis-related signature to evaluate immune features and predict prognosis in colorectal cancer.
    Li L; Sun F; Kong F; Feng Y; Song Y; Du Y; Liu F; Kong X
    Front Oncol; 2023; 13():1083956. PubMed ID: 37384293
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Identification and validation of a novel cuproptosis-related genes signature associated with prognosis, clinical implications and immunotherapy of hepatocellular carcinoma.
    He F; Zeng P; Ma S; Yang X; Liu H; Liu Q; Zhou Y; Zhu H
    Front Pharmacol; 2023; 14():1088993. PubMed ID: 36843949
    [No Abstract]   [Full Text] [Related]  

  • 43. Prognostic and Immunological Significance of the Molecular Subtypes and Risk Signatures Based on Cuproptosis in Hepatocellular Carcinoma.
    Tang X; Ren X; Huang T; Miao Y; Ha W; Li Z; Yang L; Mi D
    Mediators Inflamm; 2023; 2023():3951940. PubMed ID: 37124062
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A novel cuproptosis-related lncRNA signature predicts the prognosis and immune landscape in bladder cancer.
    Bai Y; Zhang Q; Liu F; Quan J
    Front Immunol; 2022; 13():1027449. PubMed ID: 36451815
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Molecular Characterization of Cuproptosis-related lncRNAs: Defining Molecular Subtypes and a Prognostic Signature of Ovarian Cancer.
    Li N; Yu K; Huang D; Li S; Zeng D; Li J; Fan L
    Biol Trace Elem Res; 2024 Apr; 202(4):1428-1445. PubMed ID: 37528285
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cuprotosis Programmed-Cell-Death-Related lncRNA Signature Predicts Prognosis and Immune Landscape in PAAD Patients.
    Chi H; Peng G; Wang R; Yang F; Xie X; Zhang J; Xu K; Gu T; Yang X; Tian G
    Cells; 2022 Oct; 11(21):. PubMed ID: 36359832
    [TBL] [Abstract][Full Text] [Related]  

  • 47. An integrative analysis revealing cuproptosis-related lncRNAs signature as a novel prognostic biomarker in hepatocellular carcinoma.
    Chen X; Sun M; Feng W; Chen J; Ji X; Xie M; Huang W; Chen X; Zhang B; Nie Y; Fan D; Wu K; Xia L
    Front Genet; 2023; 14():1056000. PubMed ID: 36845390
    [No Abstract]   [Full Text] [Related]  

  • 48. The potential use and experimental validation of genomic instability-related lncRNA in pancreatic carcinoma.
    Xia X; Zhao S; Song X; Zhang M; Zhu X; Li C; Chen W; Zhao D
    Medicine (Baltimore); 2023 Sep; 102(37):e35300. PubMed ID: 37713870
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A novel copper-induced cell death-related lncRNA prognostic signature associated with immune infiltration and clinical value in gastric cancer.
    Wang L; Xiao K; Dong Z; Meng T; Cheng X; Xu Y
    J Cancer Res Clin Oncol; 2023 Sep; 149(12):10543-10559. PubMed ID: 37291405
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A novel cuproptosis-related LncRNA signature: Prognostic and therapeutic value for acute myeloid leukemia.
    Li P; Li J; Wen F; Cao Y; Luo Z; Zuo J; Wu F; Li Z; Li W; Wang F
    Front Oncol; 2022; 12():966920. PubMed ID: 36276132
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A novel defined risk signature of cuproptosis-related long non-coding RNA for predicting prognosis, immune infiltration, and immunotherapy response in lung adenocarcinoma.
    Ma C; Li F; Gu Z; Yang Y; Qi Y
    Front Pharmacol; 2023; 14():1146840. PubMed ID: 37670938
    [No Abstract]   [Full Text] [Related]  

  • 52. Cuproptosis-Related lncRNA Gene Signature Establishes a Prognostic Model of Gastric Adenocarcinoma and Evaluate the Effect of Antineoplastic Drugs.
    Tu H; Zhang Q; Xue L; Bao J
    Genes (Basel); 2022 Nov; 13(12):. PubMed ID: 36553481
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Crosstalk of ferroptosis regulators and tumor immunity in pancreatic adenocarcinoma: novel perspective to mRNA vaccines and personalized immunotherapy.
    Shi Y; Wang Y; Dong H; Niu K; Zhang W; Feng K; Yang R; Zhang Y
    Apoptosis; 2023 Oct; 28(9-10):1423-1435. PubMed ID: 37369808
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A Cuproptosis-Related LncRNA Risk Model for Predicting Prognosis and Immunotherapeutic Efficacy in Patients with Hepatocellular Carcinoma.
    Wang S; Bai H; Fei S; Miao B
    Biochem Genet; 2023 Oct; ():. PubMed ID: 37898914
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comprehensive analysis of cuproptosis-related long noncoding RNA for predicting prognostic and diagnostic value and immune landscape in colorectal adenocarcinoma.
    Liu S; Zhang S; Liu Y; Yang X; Zheng G
    Hum Genomics; 2023 Mar; 17(1):22. PubMed ID: 36915193
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Construction and systematic evaluation of a machine learning-based cuproptosis-related lncRNA score signature to predict the response to immunotherapy in hepatocellular carcinoma.
    Lu D; Liao J; Cheng H; Ma Q; Wu F; Xie F; He Y
    Front Immunol; 2023; 14():1097075. PubMed ID: 36761763
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Identification of cuproptosis-related subtypes and characterization of the tumor microenvironment landscape in head and neck squamous cell carcinoma.
    Huang J; Xu Z; Yuan Z; Cheng L; Zhou C; Shen Y
    J Clin Lab Anal; 2022 Sep; 36(9):e24638. PubMed ID: 36082469
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Development and validation of cuproptosis-related lncRNA signatures for prognosis prediction in colorectal cancer.
    Pang L; Wang Q; Wang L; Hu Z; Yang C; Li Y; Wang Z; Li Y
    BMC Med Genomics; 2023 Mar; 16(1):58. PubMed ID: 36949429
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Development and Validation of an Inflammatory Response-Related Gene Signature for Predicting the Prognosis of Pancreatic Adenocarcinoma.
    Deng ZL; Zhou DZ; Cao SJ; Li Q; Zhang JF; Xie H
    Inflammation; 2022 Aug; 45(4):1732-1751. PubMed ID: 35322324
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A novel cuproptosis-related subtypes and gene signature associates with immunophenotype and predicts prognosis accurately in neuroblastoma.
    Tian XM; Xiang B; Yu YH; Li Q; Zhang ZX; Zhanghuang C; Jin LM; Wang JK; Mi T; Chen ML; Liu F; Wei GH
    Front Immunol; 2022; 13():999849. PubMed ID: 36211401
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.